-

09:28:33 AM

CRNX Stock News

CRNX - Crinetics Pharmaceuticals Inc

08/12/22 8:00 AM

Nasdaq : CRNX

earnings

Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Paltusotine’s Phase 3 PATHFNDR Program in Acromegaly and Phase 2 Program in Carcinoid Syndrome Remain on Track for Top-Line Data in 2023 CRN04894 Phase 1 Data Demonstrated Pharmacologic Proof-of-Concept for Further Development in Both Cushing’s Disease and Congenital Adrenal Hyperplasia CRN04777

RHEA-AI

neutral

08/10/22 4:44 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on August 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 67,100 shares of its common stock

RHEA-AI

very positive

08/04/22 8:00 AM

Nasdaq : CRNX

clinical trial

Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Peter J. Trainer, M.D., vice president of clinical endocrinology, will review additional analyses from the preclinical and Phase 1 clinical studies of CRN04894 in an oral presentation

RHEA-AI

neutral

07/12/22 5:09 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 12, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 107,500 shares of its common stock

RHEA-AI

very positive

06/10/22 4:30 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on June 10, 2022, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 138,500 shares of its common stock

RHEA-AI

very positive

06/08/22 7:30 AM

Nasdaq : CRNX

Crinetics Presents Clinical and Research Results at ENDO 2022

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital

RHEA-AI

neutral

06/07/22 7:30 AM

Nasdaq : CRNX

conferences

Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference

Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that company

RHEA-AI

neutral

05/25/22 7:00 AM

Nasdaq : CRNX

clinical trial

Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a

RHEA-AI

neutral

05/12/22 4:41 PM

Nasdaq : CRNX

earnings

Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update

Phase 1 Multiple-Ascending Dose Data for CRN04894 Expected in 2Q22 Paltusotine’s Phase 3 PATHFNDR Trials in Acromegaly Advancing Towards Anticipated Top-Line Data Readouts in 2023 Clinical Trial of CRN04777 in Congenital Hyperinsulinism Patients Planned to Begin in 2H22 Following Our Previous

RHEA-AI

positive

05/10/22 4:18 PM

Nasdaq : CRNX

Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that

RHEA-AI

very positive

1 2 3 4 5 6 7 Next

CRNX Data

IndustryResearch and Development in Biotechnology
Websitewww.crinetics.com
CeoR. Scott Struthers
Security nameCrinetics Pharmaceuticals Inc
Issue typecs
SectorProfessional, Scientific, and Technical Services
Sic code2834
Employees93
Tags
- Health Technology
- Pharmaceuticals: Major
Address10222 Barnes Canyon Rd Bldg 2
StateCalifornia
CitySan Diego
Zip92121-2711
CountryUnited States
Phone18584506464

About Crinetics Pharmaceuticals Inc

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate, paltusotine (formerly CRN00808), is an oral selective nonpeptide somatostatin receptor type 2 biased agonist undergoing two Phase 2 clinical trials for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. Crinetics plans to advance paltusotine into a Phase 3 trial in acromegaly and a Phase 2 trial for the treatment of carcinoid syndrome associated with NETs in 2021. The company is also developing CRN04777, an oral nonpeptide somatostatin receptor type 5 (SST5) agonist for hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease, congenital adrenal hyperplasia and other diseases of excess ACTH. All of the company's drug candidates are new chemical entities resulting from in-house drug discovery efforts and are wholly owned by the company